News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
News Tarek Samad takes on task of delivering on Lundbeck's R&D Lundbeck names Tarek Samad to replace its retiring R&D chief, Johan Luthman, and he is facing a tough task as the firm heads towards a patent cliff.
News Key pipeline drug for Lundbeck delivers in Cushing syndrome Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.
News Axsome breaks new ground in Alzheimer's with Auvelity OK Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
News Lundbeck names AI head in quest to become 'bionic' company Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.
News Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
